INVESTOR ALERT: Richtech Robotics Inc. Investors with Substantial Losses Have Opportunity to Lead the Richtech Robotics Class Action Lawsuit – RGRD Law

SAN DIEGO, Feb. 14, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Richtech Robotics Inc. (NASDAQ: RR) publicly traded securities between January 27, 2026 and 12:00 p.m. EST on January 29, 2026, inclusive (the “Class Period”), have until April 3, 2026 to seek appointment as lead plaintiff of the Richtech Robotics class action lawsuit. Captioned Diez v. Richtech Robotics Inc., No. 26-cv-00231 (D. Nev.), the Richtech Robotics class action lawsuit charges Richtech Robotics as well as certain of Richtech Robotics’ top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

Richtech Robotics

class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-richtech-robotics-inc-class-action-lawsuit-rr.html

You can also contact attorney

J.C. Sanchez

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: Richtech Robotics develops, manufactures, deploys, and sells robotic solutions for automation in the service industry.

The Richtech Robotics class action lawsuit alleges that throughout the Class Period Richtech Robotics claimed that it had a collaborative and commercial relationship with Microsoft when it did not.

The Richtech Robotics class action lawsuit further alleges that on January 29, 2026 at 12:00 p.m. EST, Hunterbrook Media published an article entitled “Breaking: Microsoft Denies Partnership with Richtech Robotics,” which alleged that “‘Richtech participated in an AI Co-Innovation Lab engagement, which is a standard customer engagement focused on exploring and prototyping AI solutions using Microsoft technologies . . . . There is no commercial element in this lab engagement.’” On this news, the price of Richtech Robotics Class B stock fell more than 29% over two trading days, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Richtech Robotics publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Richtech Robotics class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Richtech Robotics investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Richtech Robotics shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Richtech Robotics class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]



Hasbro Is ‘Inspiring a Lifetime of Play’ at 2026 Toy Fair® With Premier Collaborations, Entertainment Announcements and New Products

Hasbro Is ‘Inspiring a Lifetime of Play’ at 2026 Toy Fair® With Premier Collaborations, Entertainment Announcements and New Products

Visit Hasbro Booth #403 at the Javits Convention Center for debuts across BABY ALIVE, DUNGEONS & DRAGONS, MAGIC: THE GATHERING, MONOPOLY, NANO-MALS, NERF, PEPPA PIG, PLAY-DOH and TRANSFORMERS, as well as premier partner brands BEYBLADE X, KPop Demon Hunters, Marvel, Star Wars™ and more

Watch Hasbro’s Toy Fair Sizzle Video and Download the Product Lookbook HERE

PAWTUCKET, R.I.–(BUSINESS WIRE)–
Hasbro, a leading games, IP and toy company, returns to the North American International Toy Fair® at the Javits Convention Center in New York (February 14-17, 2026) with a dynamic slate of product reveals and franchise milestones that blend pop culture with play. Throughout the weekend, Hasbro will welcome fans and partners at Booth #403 to experience the latest across its iconic brands.

This year’s show highlights meaningful new storytelling across Hasbro’s portfolio—including the first-ever PEPPA PIG toy featuring George with his hearing aid—alongside the most ruthless version of MONOPOLY yet with MONOPOLY Deal No Mercy. Adding to the buzz are a brand-new FURBY called FURBY Vibes, adorable BABY ALIVE co-brand with Burt’s Bees, the nostalgic return of CROSSFIRE, cutting-edge innovations for action favorites BEYBLADE X, NERF and TRANSFORMERS, a deliciously creative new PLAY-DOH campaign and fresh entertainment-inspired offerings from powerhouse Disney Consumer Products brands Marvel andStar Wars™. Across every category, Hasbro is “Inspiring a Lifetime of Play” with products and experiences that spark imagination, creativity, learning, excitement and self-expression.

Hasbro also comes to Toy Fair with strong licensing momentum following recently announced agreements with Warner Bros. Discovery Global Consumer Products for Harry Potter, Netflix for KPop Demon Hunters, Legendary Entertainment for Street Fighterand Amazon MGM Studios for Voltron. These new partnerships expand Hasbro’s global influence and reinforce the company’s partner-scaled growth strategy.

“Play is evolving into a more immersive, connected experience driven by storytelling and fandom. At Hasbro, we’re inspiring a lifetime of play by creating moments that bring fans and families closer to the brands they love,” said Tim Kilpin, Hasbro’s President of Toys, Games, Licensing and Entertainment. “This year’s Toy Fair showcase highlights our growing portfolio of IP, from a robust entertainment slate with The Walt Disney Company to new KPop Demon Hunters toys, with more to come across Harry Potter, Street Fighter and Voltron. Paired with continued innovation across beloved franchises including PEPPA PIG, PLAY-DOH, TRANSFORMERS and others, our 2026 offerings are designed to engage more consumers and deepen fandom worldwide.”

In addition to its show-floor presence, Hasbro will take the Toy Fair stage with Kim Boyd, President, Global Licensing and Entertainment, participating as a panelist in “Your Guide to Licensing and Collaborations with the Key Players in the Toy Industry” on Saturday, February 14 from 3:50 PM – 4:30 PM at the Toy Fair University Theatre. During the session, Boyd will share insights into Hasbro’s licensing strategy and key focus areas for the future.

To kick off Day 1 of Toy Fair, Hasbro announces the following major brand moments and product launches debuting this year.

Partnership Announcements

  • Hasbro x Harry Potter: Hasbro announced a multi-year licensing partnership starting in 2027 with Warner Bros. Discovery Global Consumer Products (WBDGCP) to bring the Harry Potter universe to life through a range of film and HBO Original series-inspired products featuring dolls, role play, action figures & collectibles, interactive plush, board games and more to be revealed later this year.
  • Hasbro x Street Fighter™: On February 2, Hasbro announced a new licensing partnership with Legendary Entertainment timed to the highly anticipated live-action Street Fighter movie arriving in theaters October 16, 2026. The collaboration will bring the film’s iconic characters to life through a line of action figures, toys, and collectibles, extending the experience from the big screen into the hands of fans worldwide.
  • Hasbro x Voltron: On February 4,Hasbro announced a new licensing collaboration with Amazon MGM Studios to produce action figures, toys and roleplay for the studio’s upcoming live-action Voltron movie.

Product Reveals

  • BABY ALIVE: BABY ALIVE expands its nurturing play lineup with new bedtime-inspired dolls designed for comfort, connection and early caregiving. Anchored by a new co-brand with Burt’s Bees Baby, the collection introduces soft, snuggly dolls with cozy sleepwear and soothing accessories.
  • BEYBLADE X: Hasbro raises the stakes with the BEYBLADE X Sneak Attack Battle Set, featuring an all-new stadium with a pop-up rail and X-Celerator Rail that can dramatically change battles with high-speed Xtreme Dash action and explosive collisions. The lineup also introduces the BEYBLADE X Clip & Rip Launcher Set, designed for on-the-go play with a belt- and backpack-ready clip and built-in ripcord storage. Both sets launch in July 2026, giving Bladers new ways to battle anytime, anywhere. Stay tuned for more epic bursts and battles later this year.
  • CROSSFIRE: With a legacy of 55 years, we’re bringing back fun and nostalgia by getting kids and parents caught up in CROSSFIRE. In this epic shootout showdown, players rapidly blast their marbles across the arena to knock pucks into the opposing end zone. Featuring a modern arena, score tracking, and all-in-one storage, CROSSFIRE is built for action-packed fun and portability.
  • DUNGEONS & DRAGONS: DUNGEONS & DRAGONS looks to build off a strong year that attracted new players and re-energized veteran tabletop gamers with exciting partnerships like Stranger Things: Welcome to the Hellfire Club, new offerings for those looking to say yes to their first adventure like DUNGEONS & DRAGONS Starter Set: Heroes of the Borderlands, and fan favorite universes like the Forgotten Realms. 2026 will create even more excitement to surprise and delight fans both old and new, bringing D&D further into pop culture consciousness.
  • FURBY: Hasbro’s newest FURBY toy – FURBY Vibes – takes self-expression to the next level with interactive, swappable glasses that unlock three distinct vibes – Star Diva, Chill Spa, and Punk Rocker – each packed with its own music, sounds, phrases, and games. With interactive play, expressive modes, and customizable style, FURBY Vibes is a personality-packed companion that’s all about music, moods, and being unapologetically FURBY.
  • KPop Demon Hunters: Hasbro is bringing the music, magic and demon-hunting energy of Netflix’s most popular film into play, with a collection that lets fans step into the world of HUNTR/X through roleplay toys, collectibles and games. The range includes NERF gear inspired by each member’s signature weapons, IR-syncing electronic light sticks, interactive FURBY Furblets, and MONOPOLY: KPop Demon Hunters Edition for team-based game night fun.
  • MAGIC: THE GATHERING: Wizards of the Coast, and Nickelodeon have announced that the heroes in a half shell are heading into the world’s premier collectible card game as fans got the first look at Magic: The Gathering | Teenage Mutant Ninja Turtles. The upcoming Universes Beyond set launches globally on March 6 and brings decades of Turtle Power to Magic with the famous heroes along with their infamous foes and friends. For players who grew up watching the adventures of Leonardo, Raphael, Donatello and Michelangelo, they can now share those stories with a new generation of Magic players. Download the latest assets for Magic: The Gathering | Teenage Mutant Ninja Turtles here.
  • Marvel Preschool Product Lineup: Designed for kids and kids at heart, new action figures, vehicles and playsets are coming to the popular toy lines inspired by Disney Jr.’s hit series Marvel’s Spidey and his Amazing Friends and Marvel’s Iron Man and his Awesome Friends. Fans can swing into action with the new “Rescue-Webs” themed product line from season five of Spidey and his Amazing Friends that features the Rescue Webs Web-Quarters playset, and enjoy other exciting toys inspired by the new Iron Man “Giant-Sized Armor” storyline featured in upcoming episodes later this year.
  • MONOPOLY Deal No Mercy: Make bank, not friends in the most ruthless MONOPOLY Deal edition yet. MONOPOLY Deal No Mercy game brings meaner swaps, sneakier deals, and nastier schemes. Unlike in the classic MONOPOLY Deal game, a set can be stolen instantly, Action cards can be used to charge double rent and force someone to hand over their Bank, and when a player can’t pay an opponent, they must fork over a debt chip and pay them back with one of their cards.
  • NERF Rebel Ops: NERF is launching a new hero inspired line of blasters with Rebel Ops. NERF Rebel Ops is a bold new lineup that transforms classic dart battles into role-driven missions where every player becomes the main character. Inspired by the video games kids love, each Rebel Ops blaster is built around a distinct battle role and “ultimate ability,” letting players choose how they want to dominate the field, whether through power with the NERF Rebel Ops Doom Canon, the NERF Rebel Ops Deadeye blaster for defensive approach, or with the NERF Rebel Ops Ammohawk for precision, high-impact action. Rebel Ops delivers eye-catching designs, customizable attachments, and standout performance at every price point, available at most major retailers this July 2026.
  • PEPPA PIG: PEPPA PIG introduces a meaningful new storyline in Season 11 as George, Peppa’s little brother, is revealed to be moderately deaf. Developed with guidance from National Deaf Children’s Society, the Hearing Loss Association of America (HLAA), and Camilla Arnold, a deaf executive producer and script consultant, the storyline expands on PEPPA PIG’s history of representation in preschool entertainment. The story comes to life on screen this spring on Nickelodeon and in play with the PEPPA PIG Joke & Sing George Figure, the first toy to feature George with his hearing aid, available now at Amazon. The new toy assortment also includes Ready, Pedal, Go Peppa, an interactive playset that lets kids help Peppa learn to ride her bike.
  • PLAY-DOH: Imagination is served fresh with a new collection of food-themed PLAY-DOH playsets, letting kids explore creativity through pretend cooking, crafting, and storytelling. From the Super Sizzlin’ Kitchen with realistic sounds to the Wok & Wonton set, Crazy Waffle Café, Stamp and Spin Pizza Playset and sweet options like the Donut Drop Shop, each set delivers hands-on, sensory-rich fun. Rounding out the range, the Treats To Go assortment adds portable, food-shaped creativity for imaginative play anywhere.
  • The Mandalorian and Grogu Product Lineup: Enter “a galaxy far, far away….” and gear up for The Mandalorian and Grogu film release. Hasbro is launching a full slate of out of this world toys based on the highly anticipated Star Wars film, including new action figures from THE BLACK SERIES and THE VINTAGE COLLECTION product lines, as well as ACTION BUDDY GROGU, ACTIONVERSE 4.5″ FIGURES and more.
  • TRANSFORMERS: A new wave of toys to honor THE TRANSFORMERS: THE MOVIE’s40th anniversary has been revealed, including THE MATRIX OF LEADERSHIP premium electronic movie replica and STUDIO SERIES product line additions of Shockwave, Skywarp, Wheeljack, Kranix, Sunstreaker, Astrotrain and Snarl. More anniversary celebration details to follow soon.

For more information, visit the Hasbro Corporate Newsroom and follow Hasbro on LinkedIn,Instagram or Facebook.

About Hasbro

Hasbro is a leading games, IP and toy company whose mission is to create joy and community through the magic of play. With 165 years of expertise, Hasbro delivers groundbreaking play experiences and reaches more than 1 billion fans annually around the world, through physical and digital games, video games, toys, licensed consumer products, location-based entertainment, film, TV and more.

Through its franchise-first approach, Hasbro unlocks value from both new and legacy IP, including MAGIC: THE GATHERING, DUNGEONS & DRAGONS, MONOPOLY, HASBRO GAMES, NERF, TRANSFORMERS, PLAY-DOH and PEPPA PIG, as well as premier partner brands. Powered by its portfolio of thousands of iconic marks and a diversified network of partners and subsidiary studios, Hasbro brings fans together wherever they are, from tabletop to screen.

For more than a decade, Hasbro has been consistently recognized for its corporate citizenship, including being named one of the 100 Best Corporate Citizens by 3BL Media, a 2025 JUST Capital Industry Leader, one of the 50 Most Community-Minded Companies in the U.S. by the Civic 50, and a Brand that Matters by Fast Company. For more information, visit https://corporate.hasbro.com or @Hasbro on LinkedIn.

About Wizards of the Coast

Wizards of the Coast develops and publishes legendary games that inspire creativity, forge friendships and build communities of global fans. A division of Hasbro, a leading games, IP and toy company (NASDAQ: HAS), Wizards delivers premium experiences for gamers across tabletop, video games, and digital platforms based on both new and time-honored brands, including its best-known franchises MAGIC: THE GATHERING and DUNGEONS & DRAGONS, and from Hasbro’s unparalleled portfolio of thousands of iconic marks.

Wizards’ diverse studio network includes first-party developers Archetype Entertainment, Invoke Studios, Atomic Arcade and Skeleton Key as well as co-venture and license partners. Headquartered in Renton, Washington, Wizards fosters world-class talent to create unforgettable play experiences on all platforms. To learn more about Wizards, visit https://company.wizards.com or Wizards of the Coast on LinkedIn.

© 2026 Hasbro, Inc. All Rights Reserved.

Star Wars and related properties are trademarks and/or copyrights, in the United States and other countries, of Lucasfilm Ltd. and/or its affiliates. © & TM Lucasfilm Ltd

© 2026 MARVEL

Crystal Flynn | Hasbro, Inc.| [email protected]

KEYWORDS: United States North America Rhode Island New York

INDUSTRY KEYWORDS: Licensing (Entertainment) Electronic Games General Entertainment Other Entertainment Entertainment

MEDIA:

Logo
Logo

Kyndryl Holdings, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – KD

Kyndryl Holdings, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – KD

LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against Kyndryl Holdings, Inc. (“Kyndryl” or “the Company”) (NYSE: KD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of KD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: August 7, 2024 to February 9, 2026

DEADLINE: April 13, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Kyndryl’s financial statements were misstated throughout the class period. The Company’s internal controls on financial reporting were deficient. Based on these facts, Kyndryl’s public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

DBGI Announces Purchase of Existing Convertible Notes and Note Conversion Extension by Holders


Austin, Texas, Feb. 13, 2026 (GLOBE NEWSWIRE) — Digital Brands Group, Inc. (“DBG” or the “Company”) (Ticker: [NASDAQ:DBGI])
, a publicly traded company specializing in eCommerce and Fashion, today announced that existing holders of all of the Company’s Series D Preferred Stock (the “Series D Shares”) have advised the Company that these holders have entered into various private agreements regarding their respective ownership of, and rights with respect to, the Series D Shares (the “Shareholder Agreements”). Each Series D Share is convertible, at the discretion of the holder thereof, into shares of the Company’s common stock (the “Common Stock”) at a conversion price equal to, as of the date of a conversion, 80% of the lowest closing price of the Common Stock for each of the five trading days immediately prior to the date of such conversion.

The Company is not party to any of the Shareholder Agreements, but has been advised of the following with respect to their terms. Because the Company is not a party to any of the Shareholder Agreements it would have no ability to enforce their terms.

Conversion Standstill placed Certain Series D Shares

In exchange for one holder’s transfer (the “Transferring Holder”) of 4,687 Series D Shares (the “Transferred Shares”) to another holder (the “Transferee Holder”), the Transferee Holder agreed not to convert any of the 9,375 Series D Shares it currently owns, including the Transferred Shares, into shares of Common Stock until on or after 5:00 p.m. on May 31, 2026 (the “Conversion Standstill”). In further consideration for the Transferee Holder agreeing to the Conversion Standstill, the Transferring Holder also agreed to transfer and assign to the Transferee Holder certain pre-funded warrants of the Company (the “Pre-Funded Warrants”).

Based on the information provided by these holders, the Company currently understands that an aggregate of 9,375 Series D Shares are currently subject to the Conversion Standstill.

Leak-out Limitations placed on Certain total Series D Shares

In addition, the Transferee Holder agreed that from and after the expiration of the Conversion Standstill on May 31, 2026, the Transferee Holder shall not sell or transfer shares of the Common Stock issued upon conversion of its Series D Shares or exercise of the Pre-Funded Warrants to the extent that the proposed number of shares of Common Stock to be sold by the Transferee Holder would exceed, in the aggregate, on any trading day, the greater of: (A) (i) 5,000 shares or (ii) 1% of the average daily trading volume of the Common Stock on the day during which such shares are sold, during the first 20 calendar day period; (B) (i) 7,500 shares or (ii) 2% of the average daily trading volume of the Common Stock on the day during which such shares are sold , during the subsequent 20 calendar day period; and (C) (i) 10,000 shares or (ii) 3.5% of the average daily trading volume of the Common Stock on the day during which such shares are sold, thereafter (the “Leak-out Limitation”).

Based on the information provided by these holders, the Company currently understands that the shares of Common Stock issuable upon conversion of 9,375 Series D Shares are currently subject to the Leak-Out Limitation.

In another instance, two existing holders (the “Extending Holders”) that, at such time, collectively owned 2,500 Series D Shares (collectively, the “Extending Holder Shares”), granted another holder (the “Optionee Holder”) an option to purchase all of the Extending Holder Shares, and as partial consideration for granting such option, the Extending Holders received certain Pre-Funded Warrants from the Optionee Holder. Notwithstanding the fact that such proposed sale was abandoned, each Extending Holder agreed not to sell shares of Common Stock issuable upon conversion of its respective Series D Shares or upon exercise of its respective Pre-Funded Warrants on any single trading day in an amount that would exceed, in the aggregate, the greater of (X) 1% of the average daily traded volume of the common stock for the immediately preceding trading day, and (y) 2,500 shares of Common Stock (the “Extending Holders’ Leak-out”).

Based on the information provided by certain existing holders, the Company currently understands that the shares of Common Stock issuable upon conversion of 2,434 Series D Shares are currently subject to the Extending Holders’ Leak-out.

About Digital Brands Group

We offer a wide variety of apparel through numerous brands on a both direct-to-consumer and wholesale basis. We have created a business model derived from our founding as a digitally native-first vertical brand. We focus on owning the customer’s “closet share” by leveraging their data and purchase history to create personalized targeted content and looks for that specific customer cohort.

Digital Brands Group, Inc. Company Contact
Hil Davis, CEO

Email: [email protected] 
https://ir.digitalbrandsgroup.co


Forward-looking Statements

Certain statements included in this release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting DBG and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “should,” and “may” and other words and terms of similar meaning or use of future dates, however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements regarding DBG’s plans, objectives, projections and expectations relating to DBG’s operations or financial performance, and assumptions related thereto are forward-looking statements. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. DBG undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Potential risks and uncertainties that could cause the actual results of operations or financial condition of DBG to differ materially from those expressed or implied by forward-looking statements include, but are not limited to: risks arising from DBG not being party to any of the Shareholder Agreement and not being able to enforce any of the provisions contained therein; the accuracy of information provided by certain holders to the Company concerning the Shareholder Agreements; DBG’s ability to add and retain strategic partners and customers; disruption to DBGs distribution system; the financial strength of DBG’s customers; fluctuations in the price, availability and quality of raw materials and contracted products; disruption and volatility in the global capital and credit markets; perception of DBG by consumers and in the markets in which it operates; DBG’s response to changing fashion trends, evolving consumer preferences and changing patterns of consumer behavior; intense competition from online retailers; manufacturing and product innovation; increasing pressure on margins; DBG’s ability to implement its business strategy; DBG’s ability to grow its wholesale and direct-to-consumer businesses; retail industry changes and challenges; DBG’s and its vendors’ ability to maintain the strength and security of information technology systems; the risk that DBG’s facilities and systems and those of our third-party service providers may be vulnerable to and unable to anticipate or detect data security breaches and data or financial loss; DBG’s ability to properly collect, use, manage and secure consumer and employee data; stability of DBG’s manufacturing facilities and foreign suppliers; continued use by DBG’s suppliers of ethical business practices; DBG’s ability to accurately forecast demand for products; continuity of members of DBG’s management; DBG’s ability to protect trademarks and other intellectual property rights; possible goodwill and other asset impairment; DBG’s ability to execute and integrate acquisitions; changes in tax laws and liabilities; legal, regulatory, political and economic risks; adverse or unexpected weather conditions; DBG’s indebtedness and its ability to obtain financing on favorable terms, if needed, could prevent DBG from fulfilling its financial obligations; and climate change and increased focus on sustainability issues. More information on potential factors that could affect DBG’s financial results is included from time to time in DBG’s public reports filed with the SEC, including DBG’s Annual Report on Form 10-K, and Quarterly Reports on Form 10-Q, and Curren Reports on Forms8-K filed or furnished with the U.S. Securities and Exchange Commission.



Armlogi Holding Corp. Announces Second Quarter and First Half of Fiscal Year 2026 Results

WALNUT, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) — Armlogi Holding Corp. (“Armlogi” or the “Company”) (Nasdaq: BTOC), a U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions related to warehouse management and order fulfillment, today announced financial results for its fiscal 2026 second quarter and six-month period ended December 31, 2025.

Financial Results for the Three Months Ending December 31, 2025:

  • Total revenue increased 0.8% to $51.5 million for the three months ended December 31, 2025, compared to $51.1 million in the prior-year period.
  • Costs of services increased to $52.3 million for the three months ended December 31, 2025, resulting in a gross loss of $0.8 million, compared to a gross profit of $0.5 million in the prior year period. Gross margin declined to (1.5)% for the three months ended December 31, 2025 from 0.9% in the prior year period, primarily due to higher operational costs.
  • Net loss was $3.9 million, or ($0.08) per share for the three months ended December 31, 2025, compared to a net loss of $1.7 million, or ($0.04) per share, for the prior year period.

Financial Results for the Six Months Ending December 31, 2025:

  • Total revenue for the first six months ended December 31, 2025 grew 7.9% to $101.0 million, up from $93.6 million in the prior year period.
  • Gross loss for the six months ended December 31, 2025 was $3.3 million, showing a marginal improvement in gross margin to (3.2)% from (3.3)% in the prior year period.
  • Net loss was $10.4 million, or ($0.24) per share for the six months ended December 31, 2025, compared to a net loss of $6.3 million, or ($0.15) per share, for the prior year period.

Liquidity:

As of December 31, 2025, the Company had a cash and restricted cash balance of $9.4 million. During the six months ended December 31, 2025, the Company utilized its Standby Equity Purchase Agreement (SEPA) to issue 3,192,145 shares of common stock, raising an aggregate of $3.8 million to support its operations and growth initiatives.

Management Commentary

Aidy Chou, Chairman and Chief Executive Officer of Armlogi, commented, “The second quarter reflected stable revenue performance and continued first-half growth, though margins were pressured by elevated service costs. We are actively implementing cost optimization strategies and operational efficiencies to address the compression in our gross margins, including enhancing warehouse utilization and integrating higher-margin logistics solutions. We remain confident in our long-term strategy and our ability to create value for our stockholders as we navigate the current market dynamics.”

About Armlogi Holding Corp.

Armlogi Holding Corp., based in Walnut, CA, is a U.S.-based warehousing and logistics service provider offering a comprehensive suite of supply-chain solutions, including warehouse management and order fulfillment. The Company caters to cross-border e-commerce merchants seeking to establish U.S. market warehouses. With 10 warehouses totaling over 3.5 million square feet, the Company offers comprehensive one-stop warehousing and logistics services. The Company’s warehouses are equipped with facilities and technology to handle and store large, bulky items. Armlogi is a member of the Russell Microcap® Index. For more information, please visit www.armlogi.com.          

Forward-Looking Statements

This press release contains forward-looking statements. In addition, our representatives may from time to time make forward-looking statements, orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings growth; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us.

Company Contact:

[email protected]

Investor Relations Contact:

Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: [email protected]

*** tables follow ***

   
   
ARMLOGI HOLDING CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS 
AS OF DECEMBER 31, 2025 AND JUNE 30, 2025
(US$, except share data, or otherwise noted)
 
   
    December 31,

2025
    June 30,

2025
 
    US$     US$  
    Unaudited     Audited  
Assets            
Current assets            
Cash and cash equivalents     5,041,971         9,190,277  
Accounts receivable and other receivable, net of credit loss allowance of $594,869 and $594,869     19,477,733         22,207,500  
Other current assets     1,264,311         998,925  
Prepaid expenses     1,275,823         1,375,646  
Loan receivables, net of credit loss allowance of $nil and $nil     2,139,787         3,893,563  
Total current assets     29,199,625         37,665,911  
Non-current assets                
Restricted cash – non-current     4,394,812         4,387,550  
Property and equipment, net     10,587,255         11,259,820  
Intangible assets, net     31,370         54,627  
Right-of-use assets – operating leases     106,496,289         115,361,185  
Right-of-use assets – finance leases     1,516,794         745,547  
Other non-current assets     835,691         739,555  
Total assets     153,061,836         170,214,195  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
Liabilities:                
Current liabilities                
Accounts payable and accrued liabilities     9,385,551         9,604,783  
Contract liabilities     628,790         939,097  
Accrued payroll liabilities     491,377         283,150  
Convertible notes             5,292,749  
Operating lease liabilities – current     33,713,304         29,280,907  
Finance lease liabilities – current     763,696         386,327  
Total current liabilities     44,982,718         45,787,013  
Non-current liabilities                
Operating lease liabilities – non-current     88,755,383         98,939,552  
Finance lease liabilities – non-current     802,032         397,692  
Total liabilities     134,540,133         145,124,257  
                 
Commitments and contingencies                
Stockholders’ equity                
Common stock, US$0.00001 par value, 100,000,000 shares authorized, 45,443,079 and 42,250,934 issued and outstanding as of December 31, 2025 and June 30, 2025, respectively     454         422  
Additional paid-in capital     20,468,826         16,668,858  
Retained earnings     (1,947,577 )       8,420,658  
Total stockholders’ equity     18,521,703         25,089,938  
Total liabilities and stockholders’ equity     153,061,836         170,214,195  
                   

ARMLOGI HOLDING CORP.

CONDENSED CONSOLIDATED STATEMENTS

OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2025 AND 2024

(US$, except share data, or otherwise noted)

    Three Months

Ended

December 31,

2025
  Three Months

Ended

December 31,

2024
  Six Months

Ended

December 31,

2025
  Six Months

Ended

December 31,

2024
    US$   US$   US$   US$
    Unaudited   Unaudited   Unaudited   Unaudited
Revenue   51,542,848       51,143,682       101,016,027       93,625,578    
Costs of services   52,313,114       50,660,690       104,270,376       96,749,376    
Gross profit   (770,266 )     482,992       (3,254,349 )     (3,123,798 )  
                         
Operating costs and expenses:                        
General and administrative   3,328,550       2,659,156       7,545,856       6,327,981    
Total operating costs and expenses   3,328,550       2,659,156       7,545,856       6,327,981    
                         
Loss from operations   (4,098,816 )     (2,176,164 )     (10,800,205 )     (9,451,779 )  
                         
Other (income) expenses:                        
Other income, net   (302,280 )     (564,656 )     (1,040,872 )     (1,770,321 )  
Loss on Disposal of Assets         43,625             43,625    
Finance costs   44,121       79,989       592,466       88,997    
Total other (income) expenses   (258,159 )     (441,042 )     (448,406 )     (1,637,699 )  
                         
Loss before provision for income taxes   (3,840,657 )     (1,735,122 )     (10,351,799 )     (7,814,080 )  
                         
Current income tax expense   19,525             16,436          
Deferred income tax (recovery) expense         (75,882 )           (1,506,969 )  
Total income tax (recovery) expenses   19,525       (75,882 )     16,436       (1,506,969 )  
Net loss   (3,860,182 )     (1,659,240 )     (10,368,235 )     (6,307,111 )  
Total comprehensive loss   (3,860,182 )     (1,659,240 )     (10,368,235 )     (6,307,111 )  
                         
Basic & diluted net loss per share   (0.08 )     (0.04 )     (0.24 )     (0.15 )  
Weighted average number of shares of common stock-basic and diluted   45,443,079       41,642,442       43,952,643       41,638,221    

   
ARMLOGI HOLDING CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 
FOR THE SIX MONTHS ENDED DECEMBER 31, 2025 AND 2024 (UNAUDITED)
(US$, except share data, or otherwise noted)
 
   
    For The

Six Months Ended

December 31,

2025
    For The

Six Months Ended

December 31,

2024
 
    US$     US$  
    Unaudited     Unaudited  
Cash Flows from Operating Activities:            
Net loss     (10,368,235       (6,307,111  
Adjustments for items not affecting cash:                
Net loss from disposal of fixed assets             43,625    
Depreciation of property and equipment and right-of-use financial assets     1,679,930         1,290,471    
Amortization     23,257         17,659    
Non-cash operating leases expense     3,113,124         4,358,758    
Current estimated credit loss             228,363    
Accretion of convertible notes     527,251         72,184    
Deferred income taxes             (1,506,969  
Interest income     (39,534 )       (63,233  
Changes in operating assets and liabilities:                
Accounts receivable and other receivables     2,729,767         (5,967,431  
Other current assets     (265,386       (280,846  
Other non-current assets     (96,136       (203,643  
Prepaid expenses     99,823         249,667    
Accounts payable & accrued liabilities     (299,550       (1,969,214  
Contract liabilities     (310,307       972,381    
Income tax payable             (87,075  
Accrued payroll liabilities     208,227         (16,180  
Net changes in derecognized ROU and operating lease liabilities             (63,874  
Net cash used in operating activities     (2,997,769 )       (9,232,468 )  
                 
Cash Flows from Investing Activities:                
Purchase of property and equipment     (636,868       (2,070,770 )  
Loan disbursements     (2,770,000       (1,000,000  
Proceeds from loan repayments     4,563,310         2,036,705    
Proceeds from sale of property and equipment             25,000    
Net cash provided by (used in) investing activities     1,156,442         (1,009,065  
                 
Cash Flows from Financing Activities:                
Repayment to related parties             (350,209  
Repayments of finance lease liabilities     (279,717       (72,368  
(Repayments) Net proceeds from convertible notes     (2,020,000       8,092,473    
Net cash (used in) provided by financing activities     (2,299,717 )       7,669,896    
                 
Net decrease in cash and cash equivalents and restricted cash     (4,141,044       (2,571,637  
Cash and cash equivalents and restricted cash, beginning of the period     13,577,827         9,950,384    
Cash and cash equivalents and restricted cash, end of the period     9,436,783         7,378,747    
The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets that sum to the total of the same amounts shown in the Condensed Consolidated Statements of Cash Flows:                
Cash and cash equivalents     5,041,971         5,118,815    
Restricted cash – non-current     4,394,812         2,259,932    
Total cash and cash equivalents and restricted cash shown in the Condensed Consolidated Balance Sheets     9,436,783         7,378,747    
                 
Supplemental Disclosure of Cash Flows Information:                
Cash paid for income tax     (23,300 )       (87,074  
Cash paid for interest             (16,813  
Non-cash Transactions:                
Right-of-use assets acquired in exchange for finance lease liabilities     1,061,426            
Right-of-use assets acquired in exchange for operating lease liabilities     2,861,346         6,184,333    
Increase (Decrease) in right-of-use assets due to remeasurement of lease terms     63,896         (884,394 )  
Shares issued for Investor Notices pursuant to SEPA by reducing the convertible notes     3,800,000            
Shares issued to settle commitment fee             250,000    



BioRestorative Announces Closing of $5.0 Million Public Offering

MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the closing of its previously announced public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants have an exercise price of $0.35 per share, are immediately exercisable and will expire five years from the date of issuance.

Rodman & Renshaw LLC acted as the exclusive placement agent for the offering.

The gross proceeds to the Company from the offering were approximately $5.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for its clinical trials with respect to BRTX-100, pre-clinical research and development with respect to its ThermoStem Program, the development of its commercial biocosmeceuticals platform and for general corporate purposes and working capital.

A registration statement on Form S-1, as amended (File No. 333-293322), relating to the offering was declared effective by the Securities and Exchange Commission (the “SEC”) on February 11, 2026. The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering. A final prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained by contacting Rodman & Renshaw LLC at 600 Lexington Ave, Floor 32, New York, NY 10022, by phone at (212) 540-4414 or e-mail at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:

• Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.

• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.

• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, the Company’s intended use of proceeds from the offering, and those set forth in the Company’s latest Form 10-K, filed with the Securities and Exchange Commission and subsequent filings with the SEC. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:

Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: [email protected]



Liberty All-Star® Growth Fund, Inc. January 2026 Monthly Update

Liberty All-Star® Growth Fund, Inc. January 2026 Monthly Update

BOSTON–(BUSINESS WIRE)–
Below is the January 2026 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG).

Liberty All-Star Growth Fund, Inc.

Ticker: ASG

Monthly Update, January 2026

Investment Approach:

Fund Style: All-Cap Growth

Fund Strategy: Combines three growth style investment managers, each with a distinct capitalization focus (small-, mid- and large-cap) selected and continuously monitored by the Fund’s Investment Advisor.

Investment Managers:

  • Weatherbie Capital, LLC

    Small-Cap Growth

  • Congress Asset Management Company, LLP

    Mid-Cap Growth

  • Westfield Capital Management Company, L.P.

    Large-Cap Growth

Top 20 Holdings at Month-End:

 

 

(37.7% of equity portfolio)

 

1

 

NVIDIA Corp.

4.7%

2

 

Apple, Inc.

2.9%

3

 

Alphabet, Inc.

2.8%

4

 

Microsoft Corp.

2.4%

5

 

Amazon.com, Inc.

2.1%

6

 

Meta Platforms, Inc.

2.0%

7

 

AAR Corp.

2.0%

8

 

FirstService Corp.

1.9%

9

 

Ollie’s Bargain Outlet Holdings, Inc.

1.7%

10

 

StepStone Group, Inc.

1.6%

11

 

Curtiss-Wright Corp.

1.6%

12

 

Artivion, Inc.

1.4%

13

 

Ascendis Pharma A/S

1.4%

14

 

Casella Waste Systems, Inc.

1.4%

15

 

Monolithic Power Systems, Inc.

1.4%

16

 

Semtech Corp.

1.3%

17

 

VSE Corp.

1.3%

18

 

Penumbra, Inc.

1.3%

19

 

Broadcom Inc.

1.3%

20

 

nVent Electric PLC

1.2%

Holdings are subject to change.

Monthly Performance:

Performance

NAV

 

Market Price

 

Discount

Beginning of month value

$5.86

 

$5.30

 

-9.6%

Distributions (Ex-Date January 22nd)

$0.12

 

$0.12

 

 

End of month value

$5.77

 

$5.25

 

-9.0%

Performance for month

0.71%

 

1.32%

 

Performance year-to-date

0.71%

 

1.32%

 

 

Net Assets at Month-End ($millions):

Total

$362.8

Equities

$364.8

Percent Invested

100.5%

Sector Breakdown* (% of equity portfolio):

Information Technology

26.7%

Industrials

25.4%

Health Care

14.8%

Consumer Discretionary

13.6%

Financials

9.9%

Communication Services

6.1%

Real Estate

2.4%

Consumer Staples

1.1%

Total Market Value

100.0%

*Based on Standard & Poor’s and MSCI Global Industry Classification Standard (GICS).

New Holdings:

Arista Networks, Inc.

DigitalOcean Holdings, Inc.

Expedia, Inc.

Fifth Third Bancorp

Karman Holdings, Inc.

Marriott International, Inc., Class A

MKS, Inc.

Morgan Stanley

Stride, Inc.

York Space Systems, Inc.

Holdings Liquidated:

Advanced Micro Devices, Inc.

Bank of America Corp.

Garmin Ltd.

Legend Biotech Corp.

Natera, Inc.

Oracle Corp.

Sprouts Farmers Market, Inc.

The net asset value (NAV) of a closed-end fund is the market value of the underlying investments (i.e., stocks and bonds) in the Fund’s portfolio, minus liabilities, divided by the total number of Fund shares outstanding. However, the Fund also has a market price; the value at which it trades on an exchange. If the market price is above the NAV the Fund is trading at a premium. If the market price is below the NAV the Fund is trading at a discount.

Performance returns for the Fund are total returns, which includes dividends, and are net of management fees and other Fund expenses. Returns are calculated assuming that a shareholder reinvested all distributions. Past performance cannot predict future investment results.

Performance will fluctuate with changes in market conditions. Current performance may be lower or higher than the performance data shown. Performance information shown does not reflect the deduction of taxes that shareholders would pay on Fund distributions or the sale of Fund shares. Shareholders must be willing to tolerate significant fluctuations in the value of their investment. An investment in the Fund involves risk, including loss of principal.

Sources of distributions to shareholders may include ordinary dividends, long-term capital gains and return of capital. The final determination of the source of all distributions in 2026 for tax reporting purposes will be made after year end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during its fiscal year and may be subject to changes based on tax regulations. Based on current estimates no portion of the distributions consist of a return of capital. These estimates may not match the final tax characterization (for the full year’s distributions) contained in shareholder 1099-DIV forms after the end of the year.

All data is as of January 31, 2026 unless otherwise noted.

Liberty All-Star® Growth Fund, Inc.

1-800-241-1850

www.all-starfunds.com

[email protected]

KEYWORDS: United States North America New York Massachusetts

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo
Logo

Liberty All-Star® Equity Fund January 2026 Monthly Update

Liberty All-Star® Equity Fund January 2026 Monthly Update

BOSTON–(BUSINESS WIRE)–
Below is the January 2026 Monthly Update for the Liberty All-Star Equity Fund (NYSE: USA).

Liberty All-Star Equity Fund

Ticker: USA

Monthly Update, January 2026

Investment Approach:

Fund Style: Large-Cap Core

Fund Strategy: Combines three value-style and two growth-style investment managers. Those selected demonstrate a consistent investment philosophy, decision making process, continuity of key people and above-average long-term results compared to managers with similar styles.

Investment Managers:

Value Managers:

  • Aristotle Capital Management, LLC

  • Fiduciary Management, Inc.

  • Pzena Investment Management, LLC

Growth Managers:

  • Sustainable Growth Advisers, LP

  • TCW Investment Management Company

Top 20 Holdings at Month-End:

 

     

(37.1% of equity portfolio)

     

 

1

     

NVIDIA Corp.

     

5.0%

2

     

Alphabet, Inc.

     

4.5%

3

     

Microsoft Corp.

     

4.0%

4

     

Amazon.com, Inc.

     

2.7%

5

     

Capital One Financial Corp.

     

2.0%

6

     

Meta Platforms, Inc.

     

1.8%

7

     

Broadcom Inc.

     

1.6%

8

     

Charles Schwab Corp.

     

1.6%

9

     

Visa, Inc.

     

1.5%

10

     

Wells Fargo & Co.

     

1.3%

11

     

Fresenius Medical Care AG

     

1.3%

12

     

S&P Global, Inc.

     

1.2%

13

     

Synopsys, Inc.

     

1.2%

14

     

Ferguson Enterprises, Inc.

     

1.1%

15

     

CVS Health Corp.

     

1.1%

16

     

Baxter International, Inc.

     

1.1%

17

     

Booking Holdings, Inc.

     

1.1%

18

     

Mastercard, Inc.

     

1.0%

19

     

Avery Dennison Corp.

     

1.0%

20

     

Parker-Hannifin Corp.

     

1.0%

Holdings are subject to change.

Monthly Performance:

Performance

NAV

Market Price

Discount

Beginning of month value

$6.84

$6.28

-8.2%

Distributions (Ex-Date January 22nd)

$0.18

$0.18

 

End of month value

$6.65

$6.06

-8.9%

Performance for month

0.11%

-0.64%

 

Performance year-to-date

0.11%

-0.64%

 

Net Assets at Month-End ($millions):

Total

     

$2,005.8

Equities

     

$2,019.9

Percent Invested

     

100.7%

Sector Breakdown* (% of equity portfolio):

Information Technology

23.8%

Financials

19.9%

Health Care

13.3%

Consumer Discretionary

10.8%

Industrials

10.4%

Communication Services

7.5%

Consumer Staples

5.4%

Materials

5.3%

Energy

1.8%

Utilities

1.2%

Real Estate

0.6%

Total Market Value

100.0%

*Based on Standard & Poor’s and MSCI Global Industry Classification Standard (GICS).

New Holdings:

Motorola Solutions, Inc.

Holdings Liquidated:

SLB, Ltd.

The net asset value (NAV) of a closed-end fund is the market value of the underlying investments (i.e., stocks and bonds) in the Fund’s portfolio, minus liabilities, divided by the total number of Fund shares outstanding. However, the Fund also has a market price; the value at which it trades on an exchange. If the market price is above the NAV the Fund is trading at a premium. If the market price is below the NAV the Fund is trading at a discount.

Performance returns for the Fund are total returns, which includes dividends, and are net of management fees and other Fund expenses. Returns are calculated assuming that a shareholder reinvested all distributions. Past performance cannot predict future investment results.

Performance will fluctuate with changes in market conditions. Current performance may be lower or higher than the performance data shown. Performance information shown does not reflect the deduction of taxes that shareholders would pay on Fund distributions or the sale of Fund shares. Shareholders must be willing to tolerate significant fluctuations in the value of their investment. An investment in the Fund involves risk, including loss of principal.

Sources of distributions to shareholders may include ordinary dividends, long-term capital gains and return of capital. The final determination of the source of all distributions in 2026 for tax reporting purposes will be made after year end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during its fiscal year and may be subject to changes based on tax regulations. Based on current estimates a portion of the distributions consist of a return of capital. These estimates may not match the final tax characterization (for the full year’s distributions) contained in shareholder 1099-DIV forms after the end of the year.

All data is as of January 31, 2026 unless otherwise noted.

Liberty All-Star® Equity Fund

1-800-241-1850

www.all-starfunds.com

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo

Avista Makes Annual Price Adjustment Filing in Idaho

Request would result in higher electric prices effective May 1, 2026

SPOKANE, Wash., Feb. 13, 2026 (GLOBE NEWSWIRE) — Avista (NYSE: AVA) has made an annual rate adjustment filing with the Idaho Public Utilities Commission (IPUC or Commission) that if approved, is designed to increase overall electric revenues by approximately $25.2 million or 7.4% effective May 1, 2026. This filing has no impact on Avista’s earnings.

The proposed rate adjustment modifies the level of funding for Avista’s electric energy efficiency programs. This adjustment aligns the amount that is collected in customer rates with the actual costs to operate the programs. Avista’s energy efficiency programs are designed to provide a financial incentive or rebate for cost-effective energy efficiency measures. The rate changes proposed reflect the required level of funding needed to operate the programs in the coming year, and to recover costs spent in 2025 that exceeded the levels included in rates. The electric rate adjustment is designed to increase the amount collected from customers by $25.2 million or 7.4%.

Customer Bills Resulting from these Filings

If the electric Energy Efficiency filing is approved, residential electric customers in Idaho using an average of 939 kilowatt hours per month would see their monthly bills increase from $115.54 to $124.44, an increase of $8.90 per month, or approximately 7.7%. The requested electric rate change by rate schedule is as follows:

Residential Service – Schedule 1 7.4%
General Service – Schedules 11 & 12 7.3%
Large General Service – Schedules 21 & 22 7.1%
Extra Large General Service – Schedule 25 7.5%
Extra Large General Service – Schedule 25P 7.9%
Pumping Service – Schedules 31 & 32 7.2%
Street & Area Lights – Schedules 41-49 7.1%
Overall  7.4%
 

Rate Application Procedure

Avista’s applications are proposals, subject to public review and a Commission decision. Copies of the applications are available for public review at the offices of both the Commission and Avista, and on the Commission’s website (www.puc.idaho.gov). Customers may file with the Commission written comments related to Avista’s filings. Customers may also subscribe to the Commission’s RSS feed (http://www.puc.idaho.gov/rssfeeds/rss.htm) to receive periodic updates via e-mail about the case. Copies of rate filings are also available on Avista’s website at www.myavista.com/rates.

If you would like to submit comments on the proposed rate change, you can do so by going to the Commission website or mailing comments to:

Idaho Public Utilities Commission

P.O. Box 83720

Boise, ID 83720-0074

About Avista Corp.

Avista Corp. is an energy company involved in the production, transmission and distribution of energy as well as other energy-related businesses. Avista Utilities is our operating division that provides electric service to 422,000 customers and natural gas to 383,000 customers. Our service territory covers 30,000 square miles in eastern Washington, northern Idaho and parts of southern and eastern Oregon, with a population of 1.7 million. AERC is an Avista subsidiary that, through its subsidiary AEL&P, provides retail electric service to 18,000 customers in the city and borough of Juneau, Alaska. Our stock is traded under the ticker symbol “AVA.” For more information about Avista, please visit www.avistacorp.com.

This news release contains forward-looking statements regarding the company’s current expectations. Forward-looking statements are all statements other than historical facts. Such statements speak only as of the date of the news release and are subject to a variety of risks and uncertainties, many of which are beyond the company’s control, which could cause actual results to differ materially from the expectations. These risks and uncertainties include, in addition to those discussed herein, all of the factors discussed in the company’s and the Quarterly Report on Form 10-Q for the quarter ended and its Annual Report on Form 10-K for the year ended Dec. 31, 2025.

Avista Corp. and the Avista Corp. logo are trademarks of Avista Corporation.

SOURCE: Avista Corporation

To unsubscribe from Avista’s news release distribution, send a reply message to [email protected]

Contact:

Media: Lena Funston (509) 495-8090 [email protected]
Investors: Stacey Walters (509) 495-2046 [email protected]
Avista 24/7 Media Access (509) 495-4174



Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world’s most advanced psychedelic pharmaceutical grade manufacturers, thereby securing predictable and reliable supply of pharmaceutical grade psychedelics, as the pathway to commercialization unfolds

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its board of directors has ratified the entry into a put option agreement (the “Put Option Agreement”) with PsyLabs, a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds.

The Put Option Agreement grants PsyLabs the right, but not the obligation, to require the Company to make a further equity investment in PsyLabs by way of a share-for-share exchange at arm’s length and at fair market value, subject to the terms and conditions set out therein. The Put Option Agreement forms part of a broader strategic and commercial relationship between the parties, including licensing arrangements pursuant to which the Company may access PsyLabs’ investigational and commercial-scale manufacturing capabilities.

PsyLabs is believed to be among the world’s most advanced manufacturers of pharmaceutical-grade psychedelic compounds, with demonstrated expertise in scalable, GMP-compliant production. The Put Option Agreement provides the Company with a structured opportunity to acquire a significant equity stake in PsyLabs as its development and commercialization strategy evolves, while securing predictable, reliable, and high-quality supply of critical pharmaceutical grade psychedelics in support of future clinical and commercial programs.

The agreement reflects the strategic value delivered by PsyLabs in accelerating the development of an alternative investigational product approved by the Australian regulator for clinical trials, which significantly de-risked the Company’s clinical development pathway and mitigated supply-chain, regulatory, and execution risks. Structuring the arrangement through a put option enables the Company to preserve near-term financial flexibility in that the Company has secured strategic manufacturing access and long-term alignment without needing to deploy further significant capital upfront; thereby allowing the Company to preserve cash for clinical and regulatory execution as the pathway to commercialization unfolds.

Certain executives, including the Executive Chairman, the Chief Financial Officer and the General Counsel of the Company provide consulting services to PsyLabs in exchange for consulting fees. Collectively, such individuals own (directly and indirectly) less than 13% of the outstanding shares of PsyLabs. Certain of these individuals are also members of the board of directors of subsidiaries of PsyLabs for purposes of safeguarding the Company’s investment into the PsyLabs group. In accordance with the Company’s governance practices, the Board of Directors established a Special Committee comprised of two independent and disinterested directors to review and ratify the Put Option Agreement and the transactions contemplated therein. The Special Committee reviewed the terms of the Put Option Agreement, considered the commercial rationale for the transaction, and took into account, among other things, an independent third-party valuation of PsyLabs in reaching its determination.

About PsyLabs

PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.

PsyLabs operates from an ISO 22000-certified facility audited by the British Standards Institution, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics.

www.psylabs.life

About Psyence BioMed 

Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders. 

Learn more at www.psyencebiomed.com and on LinkedIn.

Contact Information for Psyence Biomedical Ltd.

Email: [email protected]
Media Inquiries: [email protected]
General Information: [email protected]

Investor Contact: 
Michael Kydd
Investor Relations Advisor
[email protected]

Forward Looking Statements 

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning. 

Forward-looking statements in this communication include statements regarding the Put Option Agreement with PsyLabs, including the potential exercise of the put option, any future equity investment by the Company in PsyLabs, anticipated access to PsyLabs’ investigational and commercial-scale manufacturing capabilities, expected supply arrangements for pharmaceutical-grade psychedelic compounds, the strategic and commercial benefits of the relationship, and the Company’s ability to advance its clinical development and commercialization strategy using PsyLabs as a supplier or strategic partner. These statements are based on current assumptions and expectations, including assumptions regarding the parties’ continued relationship, the satisfaction of contractual conditions, regulatory developments, the Company’s financial condition and capital resources, and the Company’s ability to maintain compliance with Nasdaq’s continued listing standards. These assumptions may prove incorrect. There can be no assurance that the Put Option Agreement will be exercised, that any equity investment will occur, that anticipated supply or manufacturing arrangements will be realized on the terms contemplated or at all, or that the Company will successfully advance its development or commercialization plans. There are numerous risks and uncertainties that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements.

These risks and uncertainties include, among others: (i) the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; (ii) potential volatility in the Company’s share price following the consolidation; (iii) changes in the regulatory, competitive, and economic landscape; and (iv) risks associated with the Company’s development plans and clinical trials. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC. 

These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements. 

The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.